Eprosartan does not affect the pharmacodynamics of warfarin.
Eprosartan is an angiotensin II receptor antagonist being developed for the treatment of hypertension and heart failure. The effect of eprosartan on the steady-state anticoagulant activity of warfarin was evaluated in 18 healthy male volunteers. Each subject's daily warfarin dose was titrated over 9 days to achieve a stable international normalized ratio (INR) of 1.3 to 1.6 by day 14. After the 14-day warfarin titration phase, subjects were randomized to receive either eprosartan 300 mg or matching placebo twice a day for 7 days. All subjects continued to take the warfarin dose established during the 14-day titration phase. The anticoagulant activity of warfarin was statistically equivalent when coadministered with eprosartan or with placebo. No serious or unexpected adverse events suggestive of abnormal bleeding occurred during coadministration of eprosartan and warfarin. As measured by the INR, there is no apparent effect of eprosartan on the anticoagulant effect of warfarin.
SmithKline Beecham Clinical Pharmacology Unit, Presbyterian Medical Center of the University of Pennsylvania Health System, Philadelphia 19104, USA.
D J
DJ
Kazierad
D E
DE
Martin
B
B
Ilson
S
S
Boike
N
N
Zariffa
A
A
Forrest
D K
DK
Jorkasky
D000179:Acrylates / Q000009:adverse effects / Q000494:pharmacology*; D000328:Adult; D000925:Anticoagulants / Q000009:adverse effects / Q000494:pharmacology*; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000494:pharmacology*; D004311:Double-Blind Method; D004347:Drug Interactions; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000494:pharmacology*; D019934:International Normalized Ratio; D008297:Male; D008875:Middle Aged; D013876:Thiophenes; D014859:Warfarin / Q000009:adverse effects / Q000494:pharmacology*
D000179:Acrylates; D000925:Anticoagulants; D000959:Antihypertensive Agents; D007093:Imidazoles; D013876:Thiophenes; C068373:eprosartan; D014859:Warfarin